13F Insight
DOSSIER · 13F-HR · Q2 2026

Sofinnova Investments, Inc.

$1.9B in tracked AUM across 57 positions as of Q2 2026.

SI
CIK 0001631134 · last filed Jun 30, 2026
Total AUM
$1.9B
as of Q2 2026
Holdings
57
—
positions
Whale Score
59
59
tracked
Activity
—
no data
changes this Q
AI Analysis · Q2 2026
Comprehensive Analysis of Sofinnova Investments, Inc. 13F Filing
Portfolio Overview

Sofinnova Investments, Inc. manages a concentrated portfolio totaling approximately $1.07 billion across 42 holdings as of the report date September 30, 2025. The firm reported a significant decrease in portfolio value of -34.6% (dropping from $1.64 billion in the previous quarter), a reduction driven by a combination of aggressive portfolio reallocation and potential market depreciation in the bio...

The portfolio exhibits a high-conviction strategy with notable concentration; the top ten holdings account for approximately 58% of total assets. The manager is highly active, evidenced by the substantial turnover this quarter: 10 new positions were initiated, 21 positions were sold completely, and 27 positions saw adjustments in share count. This high level of activity suggests a tactical approach to capital deployment rather than a passive buy-and-hold strategy.

Key Holdings
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
NTRA
Natera Inc
$421M1.6M21.8%02
VERA
Vera Therapeutics Inc
$120M2.8M6.2%03
GMAB
Genmab A/S
$111M4.0M5.7%04
G50871105
Jazz Pharmaceuticals PLC
$88M365K4.6%05
RAPP
Rapport Therapeutics Inc
$79M1.9M4.1%06
SPTX
Seaport Therapeutics Inc
$77M3.6M4.0%07
RARE
Ultragenyx Pharmaceutical In
$74M2.2M3.8%08
AVBP
Arrivent BioPharma Inc
$59M1.7M3.0%09
BIOA
BioAge Labs Inc
$56M2.3M2.9%10
BMY
Bristol-Myers Squibb Co
$51M877K2.6%

Filing history

2026Q2Jun 30
$1.9B▼ 26.5%
57 positionsView →2026Q1Mar 31
$2.6B▲ 13.4%
75 positionsView →2025Q4Dec 31
$2.3B▲ 116.8%
60 positionsView →2025Q3Sep 30
$1.1B▼ 34.6%
42 positionsView →2025Q2Jun 30
$1.6B▲ 6.8%
63 positionsLocked2025Q1Mar 31
$1.5B▲ 11.5%
65 positionsLocked2024Q4Dec 31
$1.4B▲ 9.0%
61 positionsLocked2024Q3Sep 30
$1.3B▼ 34.5%
62 positionsLocked2024Q2Jun 30
$1.9B▲ 7.2%
82 positionsLocked2024Q1Mar 31
$1.8B▲ 0.4%
74 positionsLocked2023Q4Dec 31
$1.8B▲ 12.8%
64 positionsLocked2023Q3Sep 30
$1.6B▲ 3.8%
69 positionsLocked
Showing 12 of 32